Spatial Memory Training and Cognitive Function
A legfontosabb adatok
- Ki végzi
- Douglas Mental Health University Institute
- Hol
- Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 80 fő, tervezett
- Kezdés
- 2025. jún. 15.
- Várható befejezés
- 2030. dec. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- SMIP
- A regiszteradat frissítve
- 2025. július 23.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 55 or older with a diagnosis of mild cognitive impairment (MCI), a mild memory and thinking problem. It tests a 3-month spatial memory training program.
- Életkor
- 55 years and older
- Nem
- All sexes
- A betegség stádiuma
- Diagnosed mild cognitive impairment (MCI). English or French must be the main language.
- Korábbi kezelés
- People cannot join if they use or have used antipsychotic medicine, use opioid painkillers or sleep medicines, or had brain surgery or ECT. Antidepressant, anti-anxiety, cholesterol or blood pressure medicine must have been taken for at least 3 months.
A részvétel fő kizáró okai
- Severe depression (GDS score greater than 12), current PTSD, generalized anxiety, insomnia or substance use disorder
- Stroke in the past 5 years or heart disease not stable with medicine
- Current smoker, colour-blindness, or motion sickness with virtual reality
- Brain injury in the last 24 months or general anesthesia in the past year
- Cannot have an MRI scan
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Age 55 years and above
- Primary language is English or French
- Individuals having received a diagnosis of Mild Cognitive Impairment (MCI)
Ki nem vehet részt
- Self-reported having either of the following:; Current post-traumatic stress disorder and/or generalized anxiety disorder; Substance use disorder; Significant heart disease (i.e., stroke occurring during 5 years prior to study assessment or cardiac disease non-stabilized with medication); Severe Depression, or a Geriatric Depression Scale (GDS) score greater than 12; Current insomnia disorder
- Current medications for sleep problems, or use of medications that affect sleep
- Use of antidepressant and anti-anxiety medication for less than 3 months prior to study entry
- Use of antipsychotic medication (past or current)
- Having undergone brain surgery or ECT
- Cholesterol or hypertension medication for less than 3 months or changes expected within the next 9 months
- History or presence of neurological or psychiatric disorders (other than MCI) that in the opinion of the investigator may compromise patient safety or study objectives
- Current severe medical conditions (e.g. untreated diabetes, cancer) that in the opinion of the investigator may compromise patient safety or study objectives
- Presence of any medical or psychological condition that, in the opinion of the principal investigator, may compromise the study objectives
- Use of analgesics with codeine (or other opioids)
- Self-reported colour-blindness
- General anesthesia in the past year
- Current smoker
- Suspected or confirmed traumatic brain injury during the last 24 months
- Motion sickness or intolerant to virtual reality tasks
- For female participants, severe menopausal symptoms, including hot flashes (determined from the Greene climacteric scale - any participants scoring over 15 is excluded)
- Use of computer games that are designed to help with memory or general cognition
- Presence of contra-indications for MRI scanning
Ez a vizsgálat jelenleg itt érhető el: Kanada.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Mild cognitive impairment (MCI) is often considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease (AD). Patients with MCI have subjective memory complaints corroborated by standard neuropsychological tests but remain functionally autonomous. One of the first brain regions to show AD pathology is the hippocampus (HPC). Reduction in HPC volume is a strong predictor of AD dementia. Therefore, improvement or restoration of HPC structure and function is thus an attractive target for improvement in memory and AD prevention strategies. In the current study, the investigators propose to examine the effects of a 3-month long spatial memory program on spatial memory and the hippocampus in patients diagnosed with MCI. Neuropsychological tests are also administered before and after the training to assess the effects of the intervention on cognition. In our previous research, the investigators have shown that spatial memory intervention program (SMIP) improves cognition and hippocampal based spatial memory compared to controls.
A vizsgálat 2 csoportja
- SMIPA vizsgált kezelés
Spatial Memory Intervention Program
- ControlPlacebo, összehasonlításként
The control group will receive no intervention between baseline and follow-up.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2025. július 23.